InsiderTrades

Form 4 for DMAA Drugs Made In America Acquisition Corp.

Accepted 2025-02-04 00:00:00 ET · period of report 2025-01-29 · accession 0001213900-25-010193 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2025-02-04 2025-01-29 DMAA Stockwell Lynn CEO, Executive COB, Dir, 10% S - Sale — -5.70M 4.16M -58% —
DI 2025-02-04 2025-01-29 DMAA Stockwell Lynn CEO, Executive COB, Dir, 10% J - Other — -400.0K 9.86M -4% —
DI 2025-02-04 2025-01-29 DMAA Stockwell Lynn CEO, Executive COB, Dir, 10% P - Purchase — +400.0K 10.3K New —
DI 2025-02-04 2025-01-29 DMAA Stockwell Lynn CEO, Executive COB, Dir, 10% P - Purchase — +400.0K 400.0K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Ordinary shares 2025-01-29 S D 5,698,363 — 4,158,780 I See footnote — — (F3) As of the Transaction Date, pursuant to share transfer agreements, the sponsor transferred an aggregate of 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share. (F1) Reflects the 400,000 private units owned by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
2 Common Ordinary shares 2025-01-29 J D 400,000 — 9,857,143 I See footnote — — (F2) As of the Transaction Date, the sponsor transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration. (F1) Reflects the 400,000 private units owned by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
3 Common Ordinary shares 2025-01-29 P A 400,000 — 10,257.14 I See footnote — — (F1) Reflects the 400,000 private units owned by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
4 Derivative Rights to receive ordinary shares 2025-01-29 P A 400,000 — 400,000 I See footnote — · — to — 400,000 Ordinary shares (F4) The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination. (F1) Reflects the 400,000 private units owned by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.